Monopar Therapeutics Inc.
MNPRMonopar Therapeutics Inc. in brief
Monopar Therapeutics Inc. is a listed company in the Biotechnology industry, based in Wilmette, Illinois, USA. Its market value was $487 M on 28 October 2026, which makes it the 12,670th largest listed company in the world and the 2,553rd largest in the USA on this site. In the year to December 2025 it had sales of $0 M and a net loss of $14 M. Chandler Robinson is its chief executive. Its shares trade under the symbol MNPR (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Monopar Therapeutics Inc.
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company developing an innovative treatment for Wilson disease and novel radiopharmaceuticals for oncology. Our Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Our radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging advanced cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of advanced cancers, that express urokinase plasminogen activator receptor.
We build our drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics, leveraging our scientific and clinical expertise to reduce risk and accelerate development.
From the company's annual report filed with the US SEC: read the report
Monopar Therapeutics Inc. timeline
- 2015
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2018
- •Legal Entity Identifier issuedLEI 549300QJFAI7L6YHKG83 registered.
Events of Monopar Therapeutics Inc. from SEC EDGAR and the GLEIF LEI register. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #5,012 (Jan 2022) · #5,056 (Dec 2022) · #5,458 (Jul 2023) · #4,604 (Jan 2024) · #1,381 (Mar 2026) · #2,270 (Aug 2026) · #2,556 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 3.5×
- Free cash flow yield
- —
- Net margin
- —
- Operating margin
- —
- Return on equity
- -10.0%
- Liabilities / assets
- 2.1%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-17M | $-14M | — |
| Dec 2024 | — | — | $-16M | $-16M | — |
| Dec 2023 | — | — | $-9M | $-8M | — |
| Dec 2022 | — | — | $-11M | $-11M | — |
| Dec 2021 | — | — | $-9M | $-9M | — |
| Dec 2020 | — | — | $-7M | $-6M | — |
| Dec 2019 | — | — | $-4M | $-4M | — |
| Dec 2018 | — | — | $-3M | $-3M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-12M | — | — | — | — |
| Dec 2024 | $-6M | — | — | — | — |
| Dec 2023 | $-8M | — | — | — | — |
| Dec 2022 | $-7M | — | — | — | — |
| Dec 2021 | $-7M | — | — | $-0.73 | — |
| Dec 2020 | $-5M | — | — | $-0.58 | — |
| Dec 2019 | $-3M | — | — | $-0.45 | — |
| Dec 2018 | $-3M | — | — | $-0.35 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-6M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 20268-KCurrent reportResults of operations
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Aug 12, 20268-KCurrent reportResults of operations
- Aug 12, 202610-QQuarterly report · period to Jun 2026
- Jul 22, 20268-KCurrent reportRegulation FD disclosure
- Jun 30, 20268-KCurrent reportRegulation FD disclosure
- Jun 26, 20268-KCurrent reportRegulation FD disclosure
- Jun 23, 20268-KCurrent reportShareholder vote
- May 29, 20268-KCurrent reportRegulation FD disclosure
- May 19, 20268-KCurrent reportRegulation FD disclosure
- May 14, 202610-QQuarterly report · period to Mar 2026
- May 14, 20268-KCurrent reportResults of operations
Official filings of Monopar Therapeutics Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $0 M
- Operating income
- $-17 M
- Net income
- $-14 M
For year ending December-2025
Balance sheet
- Total assets
- $141 M
- Total liabilities
- $3 M
- Total equity
- $138 M
As of December-2025
Top 100 institutional investors in Monopar Therapeutics Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Janus Henderson Group Ltd. | 1,119,413 | — | 16.52% | $89 M | Nov 16, 2026 |
| 2 | Ra Capital Management, L.P. | 667,207 | 0 (0.00%) | 9.85% | $53 M | Nov 16, 2026 |
| 3 | BlackRock, Inc. | 349,244 | +425 (+0.12%) | 5.15% | $28 M | Nov 13, 2026 |
| 4 | Saturn V Capital Management LP | 312,350 | +374 (+0.12%) | 4.61% | $25 M | Nov 16, 2026 |
| 5 | Siren, L.L.C. | 270,118 | 0 (0.00%) | 3.99% | $22 M | Nov 12, 2026 |
| 6 | State Street Corp | 229,771 | +137,220 (+148.26%) | 3.39% | $18 M | Nov 12, 2026 |
| 7 | Vanguard Capital Management LLC | 217,958 | +8,247 (+3.93%) | 3.22% | $17 M | Nov 13, 2026 |
| 8 | Polar Capital Holdings Plc | 213,811 | -658 (-0.31%) | 3.16% | $17 M | Nov 16, 2026 |
| 9 | Adage Capital Partners GP, L.L.C. | 209,195 | 0 (0.00%) | 3.09% | $17 M | Nov 16, 2026 |
| 10 | TCG Crossover Management, LLC | 202,242 | -1,085 (-0.53%) | 2.98% | $16 M | Nov 16, 2026 |
| 11 | ADAR1 Capital Management, LLC | 179,032 | -38,563 (-17.72%) | 2.64% | $14 M | Nov 16, 2026 |
| 12 | Balyasny Asset Management L.P. | 177,180 | +42,637 (+31.69%) | 2.61% | $14 M | Nov 16, 2026 |
| 13 | Wellington Management Group LLP | 173,645 | +15,208 (+9.60%) | 2.56% | $14 M | Nov 16, 2026 |
| 14 | Deerfield Management Company, L.P. | 137,591 | -186,154 (-57.50%) | 2.03% | $11 M | Nov 16, 2026 |
| 15 | Candriam S.C.A. | 129,797 | -13,542 (-9.45%) | 1.92% | $10 M | Nov 3, 2026 |
| 16 | Geode Capital Management, LLC | 119,852 | +7,274 (+6.46%) | 1.77% | $10 M | Nov 6, 2026 |
| 17 | Alyeska Investment Group, L.P. | 102,228 | +2,228 (+2.23%) | 1.51% | $8 M | Nov 16, 2026 |
| 18 | Quadrature Capital Ltd | 92,499 | New | 1.36% | $7 M | Nov 13, 2026 |
| 19 | Vivo Capital, LLC | 90,500 | 0 (0.00%) | 1.34% | $7 M | Nov 13, 2026 |
| 20 | Goldman Sachs Group Inc | 87,877 | +71,716 (+443.76%) | 1.30% | $7 M | Nov 16, 2026 |
| 21 | Ikarian Capital, LLC | 86,761 | +38,900 (+81.28%) | 1.28% | $7 M | Nov 16, 2026 |
| 22 | UBS Group AG | 85,271 | +58,012 (+212.82%) | 1.26% | $7 M | Nov 10, 2026 |
| 23 | Driehaus Capital Management LLC | 84,040 | 0 (0.00%) | 1.24% | $7 M | Nov 16, 2026 |
| 24 | Bank of New York Mellon Corp | 74,849 | -2,093 (-2.72%) | 1.10% | $6 M | Nov 5, 2026 |
| 25 | Ameriprise Financial Inc | 50,846 | +33,046 (+185.65%) | 0.75% | $4 M | Nov 16, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Millennium Management LLC | 48,607 | -1,704 (-3.39%) | 0.72% | $4 M | Nov 16, 2026 |
| 27 | Citadel Advisors LLC | 47,896 | +10,892 (+29.43%) | 0.71% | $4 M | Nov 16, 2026 |
| 28 | Longaeva Partners L.P. | 45,720 | -10,114 (-18.11%) | 0.67% | $4 M | Nov 16, 2026 |
| 29 | Jane Street Group, LLC | 43,683 | New | 0.64% | $3 M | Nov 12, 2026 |
| 30 | Woodline Partners LP | 42,960 | New | 0.63% | $3 M | Nov 16, 2026 |
| 31 | Vanguard Portfolio Management LLC | 42,832 | -5,984 (-12.26%) | 0.63% | $3 M | Nov 13, 2026 |
| 32 | Morgan Stanley | 38,037 | +20,118 (+112.27%) | 0.56% | $3 M | Nov 13, 2026 |
| 33 | Qube Research & Technologies Ltd | 37,213 | New | 0.55% | $3 M | Nov 13, 2026 |
| 34 | Northern Trust Corp | 35,190 | +549 (+1.58%) | 0.52% | $3 M | Nov 16, 2026 |
| 35 | Vanguard Fiduciary Trust Co | 31,441 | +3,161 (+11.18%) | 0.46% | $3 M | Nov 13, 2026 |
| 36 | Boothbay Fund Management, LLC | 26,026 | +11,337 (+77.18%) | 0.38% | $2 M | Nov 16, 2026 |
| 37 | Deutsche Bank AG\ | 25,461 | -5,547 (-17.89%) | 0.38% | $2 M | Nov 6, 2026 |
| 38 | HRT Financial LP | 23,367 | New | 0.34% | $2 M | Nov 13, 2026 |
| 39 | Stempoint Capital LP | 23,302 | -6,823 (-22.65%) | 0.34% | $2 M | Nov 16, 2026 |
| 40 | Two Sigma Investments, LP | 16,635 | +4,383 (+35.77%) | 0.25% | $1 M | Nov 16, 2026 |
| 41 | XTX Topco Ltd | 15,976 | +9,440 (+144.43%) | 0.24% | $1 M | Nov 16, 2026 |
| 42 | D. E. Shaw & Co., Inc. | 14,723 | New | 0.22% | $1 M | Nov 16, 2026 |
| 43 | Charles Schwab Investment Management Inc | 13,953 | 0 (0.00%) | 0.21% | $1 M | Nov 16, 2026 |
| 44 | Ishara Investments LP | 12,000 | -300 (-2.44%) | 0.18% | $1 M | Nov 16, 2026 |
| 45 | Bank Of America Corp /de/ | 10,689 | +7,439 (+228.89%) | 0.16% | $1 M | Nov 16, 2026 |
| 46 | Engineers Gate Manager LP | 10,341 | +6,862 (+197.24%) | 0.15% | $1 M | Nov 16, 2026 |
| 47 | Verdad Advisers, LP | 8,409 | New | 0.12% | $1 M | Nov 16, 2026 |
| 48 | BNP Paribas Financial Markets | 8,018 | +7,277 (+982.05%) | 0.12% | $1 M | Nov 12, 2026 |
| 49 | Creative Planning | 7,977 | +209 (+2.69%) | 0.12% | $1 M | Nov 2, 2026 |
| 50 | Squarepoint Ops LLC | 7,738 | New | 0.11% | $1 M | Nov 9, 2026 |
| 51 | State Of Wisconsin Investment Board | 7,351 | New | 0.11% | $1 M | Nov 16, 2026 |
| 52 | ExodusPoint Capital Management, LP | 7,277 | New | 0.11% | $1 M | Nov 16, 2026 |
| 53 | Nuveen, LLC | 7,094 | +1,114 (+18.63%) | 0.10% | $1 M | Nov 10, 2026 |
| 54 | Gsa Capital Partners LLP | 6,706 | -826 (-10.97%) | 0.10% | $1 M | Nov 16, 2026 |
| 55 | Rafferty Asset Management, LLC | 5,959 | New | 0.09% | $0 M | Nov 13, 2026 |
| 56 | Magnetar Financial LLC | 5,777 | New | 0.09% | $0 M | Nov 13, 2026 |
| 57 | American Century Companies Inc | 5,606 | +3,137 (+127.06%) | 0.08% | $0 M | Nov 12, 2026 |
| 58 | Gerber, LLC | 5,601 | 0 (0.00%) | 0.08% | $0 M | Oct 21, 2026 |
| 59 | Rhumbline Advisers | 5,600 | -30 (-0.53%) | 0.08% | $0 M | Nov 10, 2026 |
| 60 | Virtus Investment Advisers, LLC | 5,309 | -165 (-3.01%) | 0.08% | $0 M | Nov 12, 2026 |
| 61 | State Board Of Administration Of Florida Retirement System | 5,300 | 0 (0.00%) | 0.08% | $0 M | Nov 13, 2026 |
| 62 | Trexquant Investment LP | 4,957 | -7,047 (-58.71%) | 0.07% | $0 M | Nov 16, 2026 |
| 63 | Jpmorgan Chase & Co | 3,979 | +1,473 (+58.78%) | 0.06% | $0 M | Nov 12, 2026 |
| 64 | Price T Rowe Associates Inc /MD/ | 3,699 | 0 (0.00%) | 0.05% | $0 M | Nov 16, 2026 |
| 65 | MetLife Investment Management, LLC | 2,908 | 0 (0.00%) | 0.04% | $0 M | Nov 16, 2026 |
| 66 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 2,620 | +544 (+26.20%) | 0.04% | $0 M | Nov 16, 2026 |
| 67 | Axq Capital, LP | 2,566 | New | 0.04% | $0 M | Nov 12, 2026 |
| 68 | Citigroup Inc | 2,462 | +374 (+17.91%) | 0.04% | $0 M | Nov 4, 2026 |
| 69 | New York State Common Retirement Fund | 2,400 | 0 (0.00%) | 0.04% | $0 M | Nov 17, 2026 |
| 70 | Persistent Asset Partners Ltd | 1,899 | +628 (+49.41%) | 0.03% | $0 M | Nov 13, 2026 |
| 71 | Barclays PLC | 1,893 | -3,940 (-67.55%) | 0.03% | $0 M | Nov 6, 2026 |
| 72 | Vanguard Global Advisers, LLC | 1,845 | +292 (+18.80%) | 0.03% | $0 M | Nov 13, 2026 |
| 73 | Meeder Asset Management Inc | 1,651 | +262 (+18.86%) | 0.02% | $0 M | Nov 10, 2026 |
| 74 | Quarry LP | 1,500 | -2 (-0.13%) | 0.02% | $0 M | Nov 16, 2026 |
| 75 | Russell Investments Group, Ltd. | 1,451 | -13,399 (-90.23%) | 0.02% | $0 M | Nov 6, 2026 |
| 76 | Public Employees Retirement System Of Ohio | 1,410 | New | 0.02% | $0 M | Nov 16, 2026 |
| 77 | Police & Firemen's Retirement System of New Jersey | 1,121 | -347 (-23.64%) | 0.02% | $0 M | Nov 9, 2026 |
| 78 | Wells Fargo & Company/mn | 1,099 | -2,859 (-72.23%) | 0.02% | $0 M | Nov 16, 2026 |
| 79 | Tower Research Capital LLC (TRC) | 936 | +591 (+171.30%) | 0.01% | $0 M | Nov 16, 2026 |
| 80 | NewEdge Advisors, LLC | 600 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 81 | FMR LLC | 578 | +48 (+9.06%) | 0.01% | $0 M | Nov 10, 2026 |
| 82 | Legal & General Group Plc | 425 | -40 (-8.60%) | 0.01% | $0 M | Nov 16, 2026 |
| 83 | Ameritas Investment Partners, Inc. | 409 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 84 | Royal Bank Of Canada | 362 | +226 (+166.18%) | 0.01% | $0 M | Nov 16, 2026 |
| 85 | Allworth Financial LP | 117 | +6 (+5.41%) | 0.00% | $0 M | Nov 17, 2026 |
| 86 | Sterling Capital Management LLC | 104 | +32 (+44.44%) | 0.00% | $0 M | Oct 22, 2026 |
| 87 | C M Bidwell & Associates LTD | 94 | 0 (0.00%) | 0.00% | $0 M | Nov 17, 2026 |
| 88 | California State Teachers Retirement System | 62 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 89 | Superior Planning, LLC | 42 | — | 0.00% | $0 M | Nov 12, 2026 |
| 90 | GAMMA Investing LLC | 39 | +14 (+56.00%) | 0.00% | $0 M | Oct 8, 2026 |
| 91 | Arax Advisory Partners | 32 | +29 (+966.67%) | 0.00% | $0 M | Nov 12, 2026 |
| 92 | Global Retirement Partners, LLC | 32 | 0 (0.00%) | 0.00% | $0 M | Nov 10, 2026 |
| 93 | Osaic Holdings, Inc. | 24 | New | 0.00% | $0 M | Nov 12, 2026 |
| 94 | Farther Finance Advisors, LLC | 24 | 0 (0.00%) | 0.00% | $0 M | Oct 8, 2026 |
| 95 | US Bancorp \de\ | 21 | +15 (+250.00%) | 0.00% | $0 M | Nov 5, 2026 |
| 96 | Parkside Financial Bank & Trust | 13 | New | 0.00% | $0 M | Oct 27, 2026 |
| 97 | PNC Financial Services Group, Inc. | 7 | +1 (+16.67%) | 0.00% | $0 M | Nov 6, 2026 |
| 98 | Jones Financial Companies Lllp | 7 | New | 0.00% | $0 M | Nov 13, 2026 |
| 99 | SJS Investment Consulting Inc. | 6 | New | 0.00% | $0 M | Oct 26, 2026 |
| 100 | Fortitude Family Office, LLC | 5 | New | 0.00% | $0 M | Oct 14, 2026 |
Mutual funds holding Monopar Therapeutics Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 159,786 | $15 M | 2.4% | <0.01% | −4.9% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 118,700 | $11 M | 1.8% | 0.01% | +8.5% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 49,332 | $5 M | 0.73% | 0.02% | +13% | Jul 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 44,311 | $4 M | 0.65% | <0.01% | −0.4% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 31,751 | $3 M | 0.47% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 BNY Mellon Small/Mid Cap Growth FundBNY Mellon Investment Funds I | 23,890 | $2 M | 0.35% | 0.25% | −8.9% | Jun 30, 2026 |
| 🇺🇸 Neuberger Small Cap Growth FundNeuberger Berman Investment Advisers LLC | 25,313 | $2 M | 0.37% | 0.24% | +27% | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 22,728 | $1 M | 0.34% | <0.01% | +0.6% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 15,148 | $1 M | 0.22% | 0.09% | +36% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 20,497 | $1 M | 0.30% | <0.01% | −1.5% | May 31, 2026 |
| 🇺🇸 Vanguard U.S. Momentum Factor ETFThe Vanguard Group, Inc. | 19,767 | $1 M | 0.29% | 0.07% | +0.1% | May 31, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 10,953 | $1 M | 0.16% | 0.02% | +15% | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 10,465 | $1 M | 0.15% | <0.01% | −70% | Jun 30, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 7,737 | $1 M | 0.11% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 5,980 | $1 M | 0.09% | 0.02% | +7.7% | Jul 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 7,192 | $0 M | 0.11% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 4,914 | $0 M | 0.07% | 0.01% | +0.7% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 4,745 | $0 M | 0.07% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 5,952 | $0 M | 0.09% | <0.01% | +3.4% | May 31, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 3,000 | $0 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 3,000 | $0 M | 0.04% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 4,095 | $0 M | 0.06% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 4,092 | $0 M | 0.06% | 0.02% | −2.4% | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 2,647 | $0 M | 0.04% | <0.01% | −14% | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 2,170 | $0 M | 0.03% | 0.02% | +11% | Jul 31, 2026 |
| 🇺🇸 Gabelli Healthcare & WellnessRx TrustGabelli Funds, LLC | 2,500 | $0 M | 0.04% | 0.15% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 2,123 | $0 M | 0.03% | <0.01% | +5.5% | Jul 31, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 2,430 | $0 M | 0.04% | 0.01% | +136% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 2,190 | $0 M | 0.03% | 0.01% | +19% | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGoldman Sachs Asset Management, L.P. | 3,112 | $0 M | 0.05% | 0.02% | −35% | May 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 2,105 | $0 M | 0.03% | <0.01% | −28% | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 1,724 | $0 M | 0.03% | <0.01% | +71% | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 1,452 | $0 M | 0.02% | <0.01% | +6.2% | Jul 31, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 1,680 | $0 M | 0.02% | <0.01% | +500% | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 1,622 | $0 M | 0.02% | 0.01% | +67% | Jun 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 1,532 | $0 M | 0.02% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 1,500 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Spectrum FundMeeder Asset Management, Inc. | 1,389 | $0 M | 0.02% | 0.05% | +118% | Jun 30, 2026 |
| 🇺🇸 BNY Mellon Small Cap Multi-Strategy FundBNY Mellon Investment Adviser, Inc. | 1,887 | $0 M | 0.03% | 0.09% | −13% | May 31, 2026 |
| 🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC | 1,267 | $0 M | 0.02% | 0.05% | no change | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 1,184 | $0 M | 0.02% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 1,590 | $0 M | 0.02% | <0.01% | −22% | May 31, 2026 |
| 🇺🇸 Goldman Sachs Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P. | 920 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 1,058 | $0 M | 0.02% | <0.01% | −68% | Jun 30, 2026 |
| 🇺🇸 Multi-Manager U.S. Small Cap Equity FundGoldman Sachs Asset Management, L.P. | 1,865 | $0 M | 0.03% | 0.03% | — | Apr 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 1,009 | $0 M | 0.01% | 0.04% | +26% | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 932 | $0 M | 0.01% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 1,318 | $0 M | 0.02% | <0.01% | +42% | May 31, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 922 | $0 M | 0.01% | 0.01% | +14% | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC | 859 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 AQR Small Cap Momentum Style FundAQR CAPITAL MANAGEMENT, LLC | 1,448 | $0 M | 0.02% | 0.05% | — | Mar 31, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 708 | $0 M | 0.01% | 0.01% | +15% | Jun 30, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 595 | $0 M | <0.01% | 0.02% | +0.3% | Jul 31, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 593 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 679 | $0 M | 0.01% | 0.01% | +34% | Jun 30, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 608 | $0 M | <0.01% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 519 | $0 M | <0.01% | 0.02% | no change | Jul 31, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 586 | $0 M | <0.01% | 0.01% | +17% | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 479 | $0 M | <0.01% | <0.01% | −4.8% | Jul 31, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 520 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 383 | $0 M | <0.01% | 0.02% | no change | Jul 31, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 600 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 409 | $0 M | <0.01% | 0.01% | +36% | Jun 30, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 337 | $0 M | <0.01% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 307 | $0 M | <0.01% | 0.01% | +2.7% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 420 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC | 286 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC | 229 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC | 255 | $0 M | <0.01% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS | 200 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 178 | $0 M | <0.01% | <0.01% | −40% | Jun 30, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 177 | $0 M | <0.01% | <0.01% | −69% | Jun 30, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 208 | $0 M | <0.01% | <0.01% | +5.6% | May 31, 2026 |
| 🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC | 144 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 142 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC | 163 | $0 M | <0.01% | <0.01% | −42% | May 31, 2026 |
| 🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC | 162 | $0 M | <0.01% | <0.01% | −42% | May 31, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 108 | $0 M | <0.01% | <0.01% | −2.7% | Jun 30, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 105 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC | 103 | $0 M | <0.01% | <0.01% | −71% | Jun 30, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 88 | $0 M | <0.01% | <0.01% | −72% | Jul 31, 2026 |
| 🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC | 96 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC | 135 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 State Street Balanced Index FundSSGA Funds Management, Inc. | 50 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 28 | $0 M | <0.01% | <0.01% | +3.7% | Jul 31, 2026 |
| 🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors | 19 | $0 M | <0.01% | <0.01% | −5.0% | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 86 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Monopar Therapeutics Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Kim R. TsuchimotoDirector | Option exercise10b5-1 plan | +856 | $30.00 | $26 K | 856 | Form 4 |
| filed | Kim R. TsuchimotoDirector | Option exercise10b5-1 plan | +2,035 | $14.00 | $28 K | 2,891 | Form 4 |
| filed | Kim R. TsuchimotoDirector | Sell10b5-1 plan | -1,295 | $70.75 | $92 K | 1,596 | Form 4 |
| filed | Kim R. TsuchimotoDirector | Sell10b5-1 plan | -996 | $71.35 | $71 K | 600 | Form 4 |
| filed | Kim R. TsuchimotoDirector | Sell10b5-1 plan | -600 | $72.21 | $43 K | 0 | Form 4 |
| filed | Kim R. TsuchimotoDirector | Option exercise10b5-1 plan | +1,199 | $30.00 | $36 K | 1,199 | Form 4 |
| filed | Raymond AndersonDirector | Option exercise10b5-1 plan | +1,402 | $30.00 | $42 K | 6,775 | Form 4 |
| filed | Raymond AndersonDirector | Option exercise10b5-1 plan | +1,740 | $30.00 | $52 K | 8,515 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Monopar Therapeutics Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q4 2025 | Q4 2025 | $0M |
| Q4 2024 | Q4 2025 | $0M |
Fails to deliver
- : 106 shares at $71.84
- : 3,571 shares at $72.58
- : 3,431 shares at $72.35
- : 2,628 shares at $74.23
- : 1,507 shares at $116.28
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Monopar Therapeutics Inc. scorecard#
Passes 2 of the 10 checks that could be worked out. Fiscal year 2025; market cap of Oct 28, 2026.
Valuation0 of 3
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median3.5×Price to book 3.5× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- –Free cash flow yield above 5%No free cash flow yield on file.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 1
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
- ✗Net income higher than five years earlier-$14 M-$14 M in fiscal 2025 against -$6 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$14 MNet income -$14 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-14.2%-14.2% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities51.3×Current ratio 51.26 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns1 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- ✓Dividends and buybacks above 3% of the market value7.2%Dividends and buybacks were 7.2% of the market value.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Monopar Therapeutics Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 0—— | 0—— | — | — | — | — | 0—— | 0—— | 0—— | 0—— | |
| Research and development | 9.9−23.8%— | 13+132%— | 5.6−26.2%— | 7.6+16.9%— | 6.5+59.7%— | 4.1+107%— | 2.0+10.9%— | 1.8+89.7%— | 0.9+234%— | 0.3—— | |
| General and administrative | 6.8+115%— | 3.2−2.3%— | 3.2+9.7%— | 2.9+11.8%— | 2.6+7.8%— | 2.4+3.8%— | 2.4+51.3%— | 1.6r1.6+33.5%— | 1.2+27.8%— | 0.9—— | |
| Operating expenses | 17+3.4%— | 16+83.0%— | 8.8−16.2%— | 11+15.4%— | 9.1+40.2%— | 6.5+50.5%— | 4.3+29.8%— | 3.3r3.4−79.9%— | 17+1292%— | 1.2—— | |
| Operating income | −17—— | −16—— | −8.8—— | −11—— | −9.1—— | −6.5—— | −4.3—— | −3.3r−3.4—— | −17—— | −1.2—— | |
| Interest and finance income | 3.0+639%— | 0.4−5.8%— | 0.4—— | — | — | — | — | — | — | — | |
| Net interest income | — | — | 0.4+1920%— | 0.0−11.6%— | 0.0−70.7%— | 0.1−17.2%— | 0.1−4.2%— | 0.1+114%— | 0.0+567%— | 0.0—— | |
| Income before tax | −14—— | −16—— | −8.4—— | — | — | — | — | −3.3—— | −17—— | — | |
| Income tax | 0.00.0%— | 0.00.0%— | 0.00.0%— | 0.0r0—— | 0−100%— | 0.0—— | 0—— | −0.1—— | −0.0−545%— | 0.0—— | |
| Net income including minority interests | — | — | — | −11—— | −9.1—— | — | — | — | — | — | |
| Net income attributable to shareholders | −14—— | −16—— | −8.4—— | −11—— | −9.1—— | −6.3—— | −4.2—— | −3.2—— | −17—— | −1.2—— | |
| Earnings per share, basic | -1.85—— | -4.11—— | -3.04r-0.61—— | -0.83—— | -0.73—— | -0.58—— | -0.45—— | -0.35—— | -1.89—— | — | |
| Earnings per share, diluted | — | — | — | — | -0.73—— | -0.58—— | -0.45—— | -0.35—— | -1.89—— | — | |
| Shares, weighted average (basic) | 7.4+95.5%— | 3.8+37.1%— | 2.8r14−78.3%— | 13+2.0%— | 12—— | — | — | — | — | — | |
| Shares, weighted average (diluted) | — | — | — | — | 12+13.8%— | 11+17.6%— | 9.3+0.3%— | 9.3+5.8%— | 8.8—— | — | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 62+35.0%43.9% | 46+531%76.0% | 7.3−11.2%98.9% | 8.2−59.7%61.9% | 20+21.3%98.9% | 17+26.7%99.2% | 13+91.7%99.0% | 6.9−23.3%94.2% | 9.0+333%90.4% | 2.1—71.6% | |
| Short-term investments | 61+33.7%43.3% | 46+596%75.5% | 6.5−46.3%89.1% | 12—92.1% | — | — | — | — | — | — | |
| Other current assets | 0.1−19.2%0.0% | 0.1+18.7%0.1% | 0.1+44.5%0.9% | 0.0−78.9%0.3% | 0.2+247%1.1% | 0.1+299%0.4% | 0.0—0.1% | — | — | — | |
| Current assets | 140+133%99.8% | 60+722%100% | 7.3−44.3%99.8% | 13−35.8%99.5% | 21+22.2%100% | 17+27.0%99.6% | 13+82.4%99.1% | 7.3r7.3−20.6%99.1% | 9.1+336%91.9% | 2.1—72.4% | |
| Right-of-use (leased) assets | 0.3—0.2% | 0−100%0.0% | 0.0−79.3%0.2% | 0.1—0.5% | 0—0.0% | — | — | — | — | — | |
| Total assets | 141+133%100% | 60+721%100% | 7.3−44.5%100% | 13−35.5%100% | 21+21.7%100% | 17+26.3%100% | 13+82.5%100% | 7.3−26.3%100% | 9.9+243%100% | 2.9—100% | |
| Accounts payable | 2.7+21.3%1.9% | 2.3+28.3%3.7% | 1.8−43.8%23.9% | 3.1+98.0%23.7% | 1.6+34.3%7.7% | 1.2+62.5%7.0% | 0.7+81.2%5.4% | 0.4+28.1%5.5% | 0.3+383%3.1% | 0.1—2.2% | |
| Current liabilities | 2.7−47.9%1.9% | 5.3+199%8.7% | 1.8−43.8%23.9% | 3.1+98.0%23.7% | 1.6+34.3%7.7% | 1.2+62.5%7.0% | 0.7+81.2%5.4% | 0.4+28.1%5.5% | 0.3+383%3.1% | 0.1—2.2% | |
| Lease liabilities (non-current) | 0.2—0.1% | 0—0.0% | 0−100%0.0% | 0.0—0.1% | 0—0.0% | — | — | — | — | — | |
| Non-current liabilities | — | — | — | — | — | — | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | |
| Total liabilities | 2.9−45.0%2.1% | 5.3+199%8.7% | 1.8−44.0%23.9% | 3.1+98.5%23.7% | 1.6+34.3%7.7% | 1.2+62.5%7.0% | 0.7+81.2%5.4% | 0.4+28.1%5.5% | 0.3+383%3.1% | 0.1—2.2% | |
| Retained earnings | −90—−63.6% | −76—−126% | −60—−820% | −52—−392% | −41—−201% | −32—−191% | −26—−194% | −22r−22—−296% | −18—−186% | −1.9—−64.7% | |
| Shareholders' equity | 138+150%97.9% | 55+885%91.3% | 5.6−44.6%76.1% | 10−46.7%76.3% | 19+20.7%92.3% | 16+24.3%93.0% | 13+82.5%94.6% | 6.9−28.1%94.5% | 9.6+240%96.9% | 2.8—97.8% | |
| Total liabilities and equity | 141+133%100% | 60+721%100% | 7.3−44.5%100% | 13−35.5%100% | 21+21.7%100% | 17+26.3%100% | 13+82.5%100% | 7.3−26.3%100% | 9.9+243%100% | 2.9—100% | |
| Shares outstanding | 6.7+9.7%— | 6.1+105%— | 3.0r15−77.0%— | 13+2.8%— | 13+10.0%— | 11+8.2%— | 11+14.0%— | 9.30.0%— | 9.3—— | — | |
| Cash-flow statement | |||||||||||
| Share-based compensation | 4.8+324%— | 1.1−39.9%— | 1.9+15.6%— | 1.6+11.8%— | 1.5+11.1%— | 1.3+30.6%— | 1.0+91.0%— | 0.5+73.4%— | 0.3—— | 0—— | |
| Cash from operating activities | −12—— | −6.4—— | −7.9—— | −7.2—— | −7.3r7.3—— | −4.7—— | −3.0—— | −2.7r−2.9—— | −2.6—— | −1.2—— | |
| Cash from investing activities | −63—— | −14−391%— | 4.9—— | −4.9—— | 0—— | — | — | — | — | — | |
| Shares issued | 0−100%— | 4.2+103%— | 2.1+1797%— | 0.1—— | — | 8.2—— | 0—— | 0−100%— | 4.7—— | 0—— | |
| Shares bought back | −35—— | 0—— | — | — | — | — | — | — | — | — | |
| Cash from financing activities | 92+54.4%— | 59+2825%— | 2.0+6067%— | 0.0−99.7%— | 11+33.0%— | 8.2−12.5%— | 9.3—— | −0.2r0−102%— | 9.5+655%— | 1.3—— | |
| Exchange-rate effect on cash | — | — | — | — | — | 0.0—— | −0.0—— | −0.0—— | 0—— | — | |
| Change in cash | 16−58.5%— | 39—— | −0.9—— | −12−440%— | 3.6+1.2%— | 3.5−44.3%— | 6.3—— | −2.9−142%— | 6.9+10080%— | 0.1—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | — | 0*—— | 0*—— | 0—— | — | — | — | — | — | — | — | — | — | |
| Research and development | 17+4.7%— | 4.4+71.3%— | 4.8+176%— | 3.5+112%— | 3.9*−60.3%— | 2.6+163%— | 1.7+53.0%— | 1.6+70.1%— | 9.9*+858%— | 1.0—— | 1.1—— | 1.0—— | 1.0*—— | |
| General and administrative | 8.9+54.5%— | 3.0+102%— | 1.9+24.8%— | 1.7+10.1%— | 2.2*+92.5%— | 1.5+155%— | 1.5+129%— | 1.6+108%— | 1.2*+31.2%— | 0.6—— | 0.7—— | 0.8—— | 0.9*—— | |
| Operating expenses | 25+17.9%— | 7.5+82.5%— | 6.6+105%— | 5.2+62.2%— | 6.2*−44.4%— | 4.1+160%— | 3.2+80.8%— | 3.2+86.9%— | 11*+479%— | 1.6—— | 1.8—— | 1.7—— | 1.9*—— | |
| Operating income | −25—— | −7.5—— | −6.6—— | −5.2—— | −6.2*—— | −4.1—— | −3.2—— | −3.2—— | −11*—— | −1.6—— | −1.8—— | −1.7—— | −1.9*—— | |
| Interest and finance income | 4.9+123%— | 1.3+94.0%— | 1.3+66.4%— | 1.3+123%— | 1.0*+540%— | 0.7+560%— | 0.8+963%— | 0.6+626%— | 0.1*+52.0%— | 0.1—— | 0.1—— | 0.1—— | 0.1*—— | |
| Net interest income | — | — | — | — | — | — | — | — | — | — | 0.1—— | 0.1—— | 0.1*—— | |
| Net income attributable to shareholders | −21—— | −6.2—— | −5.3—— | −3.9—— | −5.2*—— | −3.4—— | −2.5—— | −2.6—— | −11*—— | −1.3—— | −1.7—— | −1.6—— | −1.8*—— | |
| Earnings per share, basic | — | -0.72—— | -0.62—— | -0.46—— | — | -0.48—— | -0.35—— | -0.38—— | — | -0.37—— | -0.49r-0.10—— | -0.51r-0.10—— | — | |
| Shares, weighted average (basic) | 8.6+20.2%— | 8.6+20.2%— | 8.5+22.1%— | 8.5+22.2%— | — | 7.1+102%— | 7.0+99.8%— | 7.0+119%— | — | 3.5—— | 3.5r18—— | 3.2r16—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 53—40.4% | 53−58.8%40.4% | 53+33.6%39.1% | 53+32.3%38.1% | 62+35.0%43.9% | 128+2021%88.5% | 40+545%73.3% | 40+409%72.1% | 46+531%76.0% | 6.0—99.2% | 6.1—85.2% | 7.8—87.6% | 7.3—98.9% | |
| Short-term investments | 52—40.3% | 52−58.8%40.3% | 53+33.8%39.0% | 52+32.5%38.0% | 61+33.7%43.3% | 127+2100%88.4% | 39+472%73.0% | 40+381%71.7% | 46+596%75.5% | 5.8—95.5% | 6.9—95.8% | 8.2—92.2% | 6.5—89.1% | |
| Other current assets | 0.4—0.3% | 0.4+4.8%0.3% | 0.5−6.5%0.3% | 0.3−52.1%0.2% | 0.1−19.2%0.0% | 0.4+737%0.3% | 0.5+715%0.9% | 0.5+340%1.0% | 0.1+18.7%0.1% | 0.0—0.8% | 0.1—0.8% | 0.1—1.3% | 0.1—0.9% | |
| Current assets | 130—99.7% | 130−9.9%99.7% | 135+151%99.8% | 138+150%99.8% | 140+133%99.8% | 144+2274%99.9% | 54+649%99.8% | 55+518%100.0% | 60+722%100% | 6.1—100% | 7.2—100% | 8.9—100% | 7.3—99.8% | |
| Right-of-use (leased) assets | 0.4—0.3% | 0.4+244%0.3% | 0.2+82.0%0.2% | 0.2+2535%0.2% | 0.3—0.2% | 0.1—0.1% | 0.1—0.2% | 0.0—0.0% | 0−100%0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0.0—0.2% | |
| Total assets | 130—100% | 130−9.7%100% | 135+151%100% | 138+150%100% | 141+133%100% | 144+2276%100% | 54+650%100% | 55+518%100% | 60+721%100% | 6.1—100% | 7.2—100% | 8.9—100% | 7.3—100% | |
| Accounts payable | 3.0—2.3% | 3.0+16.1%2.3% | 4.0+154%3.0% | 2.5+64.7%1.8% | 2.7+21.3%1.9% | 2.6+129%1.8% | 1.6+45.4%2.9% | 1.5+4.0%2.7% | 2.3+28.3%3.7% | 1.1—18.5% | 1.1—15.2% | 1.4—16.1% | 1.8—23.9% | |
| Current liabilities | 3.0—2.3% | 3.0+16.1%2.3% | 4.0+154%3.0% | 2.5—1.8% | 2.7−47.9%1.9% | 2.6—1.8% | 1.6—2.9% | — | 5.3+199%8.7% | — | — | — | 1.8—23.9% | |
| Lease liabilities (non-current) | 0.2—0.2% | 0.2+182%0.2% | 0.1+34.2%0.1% | 0.1—0.1% | 0.2—0.1% | 0.1—0.0% | 0.1—0.1% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | — | 0—0.0% | |
| Total liabilities | 3.2—2.4% | 3.2+20.6%2.4% | 4.1+148%3.1% | 2.6+73.6%1.9% | 2.9−45.0%2.1% | 2.6+135%1.8% | 1.7+52.7%3.1% | 1.5+4.0%2.7% | 5.3+199%8.7% | 1.1—18.5% | 1.1—15.2% | 1.4—16.1% | 1.8—23.9% | |
| Retained earnings | −105—−80.5% | −105—−80.5% | −99—−73.1% | −93—−67.7% | −90—−63.6% | −84—−58.5% | −81—−150% | −78—−142% | −76—−126% | −65—−1069% | −64—−885% | −62—−694% | −60—−820% | |
| Shareholders' equity | 127—97.6% | 127−10.2%97.6% | 131+151%96.9% | 135+153%98.1% | 138+150%97.9% | 142+2762%98.2% | 52+757%96.9% | 54+617%97.3% | 55+885%91.3% | 4.9—81.5% | 6.1r6.1—84.8% | 7.5r7.5—83.9% | 5.6—76.1% | |
| Total liabilities and equity | 130—100% | 130−9.7%100% | 135+151%100% | 138+150%100% | 141+133%100% | 144+2276%100% | 54+650%100% | 55+518%100% | 60+721%100% | 6.1—100% | 7.2—100% | 8.9—100% | 7.3—100% | |
| Shares outstanding | 6.8—— | 6.8+1.5%— | 6.7+9.5%— | 6.7+9.5%— | 6.7+9.7%— | 6.7+89.0%— | 6.1−65.2%— | 6.1−65.0%— | 6.1+105%— | 3.5—— | 18—— | 17—— | 3.0r15—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 6.3+56.2%— | 2.0*+85.9%— | 1.4*+11.6%— | 1.7+24.9%— | 1.1*+296%— | 1.1*+452%— | 1.3*+283%— | 1.4+312%— | 0.3*−41.2%— | 0.2*—— | 0.3*—— | 0.3—— | 0.5*—— | |
| Cash from operating activities | −16—— | −6.2*—— | −3.2*—— | −3.5—— | −3.1r−3.4*—— | −2.4r−2.1*—— | −1.1*—— | −5.7—— | −2.0*—— | −1.1*—— | −1.7*—— | −1.7—— | −1.5*—— | |
| Cash from investing activities | −58—— | 5.5*—— | 4.1*+247%— | −5.6—— | −62*—— | −2.1*−316%— | 1.2*—— | −0.3—— | −14*−583%— | 1.0*—— | −0.0*—— | −1.0—— | 3.0*—— | |
| Shares issued | — | — | — | — | 0*−100%— | 0*—— | 0*—— | 0−100%— | 1.0*+197%— | 0*—— | −0.0*—— | 3.2—— | 0.3*—— | |
| Shares bought back | — | — | — | — | 0*—— | — | — | — | 0*—— | — | — | — | — | |
| Cash from financing activities | −1.0−101%— | 0.6*−99.4%— | −0.6*—— | −0.2—— | −0.7r−0.4*−101%— | 93r92*—— | −0.3*—— | −0.1−104%— | 56*+16680%— | −0.0*—— | −0.0*—— | 3.2—— | 0.3*—— | |
| Change in cash | −75−162%— | −0.1*−100%— | 0.2*—— | −9.3—— | −66*−265%— | 88*—— | −0.2*—— | −6.1−1227%— | 40*+2173%— | −0.1*—— | −1.7*—— | 0.5—— | 1.8*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at Monopar Therapeutics Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Chandler Robinson | $10.6 M | $17.4 M | $2.3 M | $3839 |
| 2024Chandler Robinson | $1.1 M | $2.4 M | $437 K | $186 |
| 2023Chandler Robinson | $1.8 M | −$166 K | $880 K | $14 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Monopar Therapeutics Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Acquisition or sale completed 1 · Directors and officers 2 · Material agreement 4 · New debt 1 · Unregistered share sale 2 · Shareholder vote 2 · Results announced 9
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Acquisition or sale completedMaterial agreementNew debtUnregistered share sale | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jun 2015 | $2 M | No. 1 | $2 to $10 million | 8 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at Monopar Therapeutics Inc.#
1 labor condition applications certified in fiscal 2026 for 1 positions, at a median wage of $98 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| CMC Operations AssociateLogisticians | 1 | $98 K |
Where: Wilmette, IL 1
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Monopar Therapeutics Inc
Discuss Monopar Therapeutics Inc.#
3 automatic updates and 0 member comments. Sign in to comment and react.
- Results announced on 12 November 2026automatic update · Nov 12, 2026
Monopar Therapeutics Inc. announced results on 12 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: a net loss of $6 million.
- Insider trading in October 2026automatic update · Oct 31, 2026
Directors and officers of Monopar Therapeutics Inc. reported open-market trades for October 2026 (SEC Forms 4 and 5): 1 insider sold shares worth about $659,387 in 3 trades. Awards, option exercises and shares withheld for tax are not counted.
- Mutual funds: 86 funds hold $59 millionautomatic update · Jul 31, 2026
86 mutual funds in 1 country hold shares of Monopar Therapeutics Inc. worth $59 million, about 9.7% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 40 funds added shares and 28 sold; on balance they bought $560,000. Share splits are not counted as trading.
How Monopar Therapeutics Inc. compares in Biotechnology
- Market cap$487 M · higher than 58% of 726
- Revenue$0 M · higher than 0% of 647
- Price / book3.5× · lower than 43% of 534
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Monopar Therapeutics Inc.🇺🇸 | $487 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 28, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, value.today research, SEC filing, Wikidata, SEC annual report, GLEIF register.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Monopar Therapeutics Inc.? Verify and update this profile — free
Show Monopar Therapeutics Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.